A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain

Inclusion Criteria: * Patient of either sex between 18 to 60 years of age * Patients with confirmed diagnosis of Acute Musculoskeletal spasm with Low Back Pain due to any of the following causes: 1. Spondylosis deformans 2. Prolapsed Intervertebral Disc (PID) 3. Muscle Sprains with spasms * Patients willing to take the medications as directed and willing to come for the follow-ups * Willing to comply with the protocol requirements * Willing to give the written informed consent Exclusion Criteria: * Patients associated with other lumbar spinal tract conditions such as spondylitis, fracture, cancers, severe arthritis and osteoporosis. * Muscular diseases such as myositis, poliomyelitis, muscular dystrophy and myotonia. * Other known systemic diseases affecting the neurological or endocrine. * Patients with moderate to severe hepatic impairment (defined as increase in serum bilirubin, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) by \>2.5 times the upper reference level of the laboratory values) and renal impairment (defined as increase in serum creatinine and Blood urea nitrogen by \>2.5 times the upper reference level of the laboratory values). * Patients who had taken any form of skeletal muscle relaxant in the previous 7 days. * Pregnant / Lactating woman or women of child bearing potential not following adequate contraceptive measures. * Patients with known hypersensitivity to ingredients of study/active comparators. * Patients with any previous history of or current episode of cardio-vascular disorders. * Subject known to be having any of the following disorder: renal failure, bulimia, hypo and hyperthyroidism, nephrotic syndrome, anorexia nervosa, biliary obstruction, severe cardiac dysfunction. * Uncontrolled diabetes mellitus or any other metabolic disorder. * Pediatric and pregnant patients. * Patients with history of alcoholic/substance abuse. * Treatment with any investigational drug in the preceding 4 weeks. * Patients with active or recent history of, inflammatory diseases of the gastrointestinal tract such as peptic ulcer, gastritis, regional enteritis, or ulcerative colitis. * Patients in whom acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory agents (NSAIDs) have induced asthma, rhinitis, urticaria or other allergic manifestations. * Any other condition that, in the opinion of the investigator, does not justify the inclusion of the subject in the study.